Literature DB >> 3985832

Progression of visual field defects in glaucoma. Relation to compliance with pilocarpine therapy.

P A Granström.   

Abstract

In patients with primary open-angle glaucoma, compliance with pilocarpine therapy was studied with an electronic medication monitor. The visual fields and intraocular pressure (IOP) readings were followed up retrospectively during two years before and two years after the compliance measurements. Progression of visual field defects was significantly more common in patients with capsular glaucoma than in patients with simple glaucoma. Eyes with more extensive visual field defects showed progression more often than did eyes with smaller defects, and so did eyes with a high mean IOP as compared with those with a low mean IOP. Visual field defect progression was not significantly more common among patients with "poor" than among patients with "good" compliance, which indicates that noncompliance is less important for the outcome than are the type of glaucoma, the stage of visual field defects, and the mean IOP.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3985832     DOI: 10.1001/archopht.1985.01050040071020

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  3 in total

1.  Treatment for glaucoma: adherence by the elderly.

Authors:  J H Gurwitz; R J Glynn; M Monane; D E Everitt; D Gilden; N Smith; J Avorn
Journal:  Am J Public Health       Date:  1993-05       Impact factor: 9.308

2.  Glaucoma severity and medication adherence in a county hospital population.

Authors:  Cindy Ung; Elisa Zhang; Tatyana Alfaro; Yohko Murakami; Monica Zhang; Michael I Seider; Shan C Lin; Kuldev Singh
Journal:  Ophthalmology       Date:  2013-02-28       Impact factor: 12.079

3.  Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review.

Authors:  Gregory Reardon; Sameer Kotak; Gail F Schwartz
Journal:  Patient Prefer Adherence       Date:  2011-09-23       Impact factor: 2.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.